Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CFSAN Priorities: Industry & Consumer Groups Weigh In On NDIs And More

This article was originally published in The Tan Sheet

Executive Summary

FDA should accept safety findings from outside expert panels when reviewing new dietary ingredient notifications, CHPA says in Aug. 25 comments on CFSAN priorities

Related Content

Synthetics Stance In NDI Guidance Raises Red Flag For Industry
FDA Proposes Rule On Gluten-Free Labeling
FDA Requiring GRAS-Level Safety Standards For NDI Submissions, Experts Say
Supplement GMPs, NDI Guidance Should Top CFSAN 2007 Priority List – CRN
FDA Gets Green Light For Risk-Benefit Analysis From Ephedra Ruling
AER Bill Will Provide Documented History Of Supplement Safety – Industry
CFSAN priorities
Supplement GMPs Received By OMB For 90-Day Clearance Review
FDA Guidance Clarifies Labeling For Supplements Containing Food Allergens
FDA Accomplishes A-List Goals, Will Publish NDI Guidance – CFSAN





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts